

Cerebrovascular reactivity impairment in genetic frontotemporal dementia

Ivana Kancheva*,^{1,2} Arabella Bouzigues,³ Lucy L. Russell,³ Phoebe H. Foster,³ Eve Ferry-Bolder,³ John van Swieten,⁴ Lize Jiskoot,⁴ Harro Seelaar,⁴ Raquel Sanchez-Valle,⁵ Robert Laforce Jr,⁶ Caroline Graff,^{7,8} Daniela Galimberti,^{9,10} Rik Vandenberghe,^{11,12,13} Alexandre de Mendonça,¹⁴ Pietro Tiraboschi,¹⁵ Isabel Santana,^{16,17} Alexander Gerhard,^{18,19,20} Johannes Levin,^{21,22,23} Sandro Sorbi,^{24,25} Markus Otto,²⁶ Florence Pasquier,^{27,28,29} Simon Ducharme,^{30,31} Chris R. Butler,^{32,33} Isabelle Le Ber,^{34,35,36} Elizabeth Finger,³⁷ Maria Carmela Tartaglia,³⁸ Mario Masellis,³⁹ Matthis Synofzik,^{40,41} Fermin Moreno,^{42,43} Barbara Borroni,⁴⁴ Jonathan D. Rohrer,³ Louise van der Weerd,^{2,45} James B. Rowe†,^{1,46} and Kamen A. Tsvetanov†^{1,47} on behalf of The GENFI consortium*.

1 Department of Clinical Neurosciences and Cambridge University Hospitals NHS Trust, University of Cambridge, Cambridge, UK

2 Department of Radiology, Leiden University Medical Centre, Leiden, The Netherlands

3 Dementia Research Centre, Department of Neurodegenerative Disease, UCL Queen Square Institute of Neurology, London, UK.

4 Department of Neurology, Erasmus Medical Centre, Rotterdam, The Netherlands

5 Alzheimer's disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi I Sunyer, University of Barcelona, Barcelona, Spain

6 Clinique Interdisciplinaire de Mémoire, Département des Sciences Neurologiques, CHU de Québec, and Faculté de Médecine, Université Laval, QC, Canada

7 Department of Neurobiology, Care Sciences and Society, Centre for Alzheimer Research, Division of Neurogeriatrics, Bioclinicum, Karolinska Institutet, Solna, Sweden

8 Unit for Hereditary Dementias, Theme Inflammation and Ageing, Karolinska University Hospital, Solna, Sweden

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

9 Fondazione Ca' Granda, IRCCS Ospedale Policlinico, Milan, Italy

10 University of Milan, Centro Dino Ferrari, Milan, Italy

11 Laboratory for Cognitive Neurology, Department of Neurosciences, KU Leuven, Leuven, Belgium

12 Neurology Service, University Hospitals Leuven, Leuven, Belgium

13 Leuven Brain Institute, KU Leuven, Leuven, Belgium

14 Faculty of Medicine, University of Lisbon, Lisbon, Portugal

15 Fondazione IRCCS Istituto Neurologico Carlo Besta, Milano, Italy

16 University Hospital of Coimbra (HUC), Neurology Service, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

17 Centre for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra, Coimbra, Portugal

18 Division of Psychology Communication and Human Neuroscience, Wolfson Molecular Imaging Centre, University of Manchester, Manchester, UK

19 Department of Nuclear Medicine, Centre for Translational Neuro- and Behavioural Sciences, University Medicine Essen, Essen, Germany

20 Department of Geriatric Medicine, Klinikum Hochsauerland, Arnsberg, Germany

21 Department of Neurology, Ludwig-Maximilians Universität München, Munich, Germany

22 German Centre for Neurodegenerative Diseases (DZNE), Munich, Germany

23 Munich Cluster of Systems Neurology (SyNergy), Munich, Germany

24 Department of Neurofarba, University of Florence, Italy

25 IRCCS Fondazione Don Carlo Gnocchi, Florence, Italy

26 Department of Neurology, University of Ulm, Germany

27 Univ Lille, France

28 Inserm 1172, Lille, France

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

29 *CHU, CNR-MAJ, Labex Distalz, LiCEND Lille, France*

30 *Department of Psychiatry, McGill University Health Centre, McGill University, Montreal, Québec, Canada*

31 *McConnell Brain Imaging Centre, Montreal Neurological Institute, McGill University, Montreal, Québec, Canada*

32 *Nuffield Department of Clinical Neurosciences, Medical Sciences Division, University of Oxford, Oxford, UK*

33 *Department of Brain Sciences, Imperial College London, UK*

34 *Sorbonne Université, Paris Brain Institute – Institut du Cerveau – ICM, Inserm U1127, CNRS UMR 7225, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France*

35 *Centre de référence des démences rares ou précoces, IM2A, Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France*

36 *Département de Neurologie, AP-HP - Hôpital Pitié-Salpêtrière, Paris, France*

37 *Department of Clinical Neurological Sciences, University of Western Ontario, London, ON, Canada*

38 *Tanz Centre for Research in Neurodegenerative Diseases, University of Toronto, Toronto, ON, Canada*

39 *Sunnybrook Health Sciences Centre, Sunnybrook Research Institute, University of Toronto, Toronto, Canada*

40 *Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Centre of Neurology, University of Tübingen, Tübingen, Germany*

41 *Centre for Neurodegenerative Diseases (DZNE), Tübingen, Germany*

42 *Cognitive Disorders Unit, Department of Neurology, Donostia University Hospital, San Sebastian, Spain*

43 *Neuroscience Area, Biodonostia Health Research Institute, San Sebastian, Gipuzkoa, Spain*

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

44 Neurology Unit, Department of Clinical and Experimental Sciences, University of Brescia, Brescia, Italy

45 Department of Human Genetics, Leiden University Medical Centre, Leiden, The Netherlands

46 MRC Cognition and Brain Science Unit, University of Cambridge, Cambridge, UK

47 Department of Psychology, University of Cambridge, Cambridge, UK

† *Joint senior authors*

***Corresponding author:** Ivana Kancheva, MSc, Leiden University Medical Centre, Department of Radiology, Room C-03-119, Leiden, The Netherlands; Phone number: +31(6) 870 35 106, Email address: i.k.kancheva@lumc.nl; ik413@cam.ac.uk

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

Abstract

1

2 INTRODUCTION: Cerebrovascular reactivity (CVR) is an indicator of cerebrovascular
3 health and its signature in hereditary frontotemporal dementia (FTD) remains unknown. We
4 investigated CVR in genetic FTD and its relationship to cognition.

5

6 METHODS: CVR differences were assessed between 284 pre-symptomatic and 124
7 symptomatic mutation carriers, and 265 non-carriers, using resting-state fluctuation
8 amplitudes (RSFA) on component-based and voxel-level RSFA maps. Associations and
9 interactions between RSFA, age, genetic status, and cognition were examined using
10 generalised linear models.

11

12 RESULTS: Compared to non-carriers, mutation carriers exhibited greater RSFA reductions,
13 predominantly in frontal cortex. These reductions increased with age. The RSFA in these
14 regions correlated with cognitive function in symptomatic and, to a lesser extent, pre-
15 symptomatic individuals, independent of disease stage.

16

17 DISCUSSION: CVR impairment in genetic FTD predominantly affects frontal cortical areas,
18 and its preservation may yield cognitive benefits for at-risk individuals. Cerebrovascular
19 health may be a potential target for biomarker identification and disease-modifying efforts.

20

21 *Keywords:* genetic frontotemporal dementia, functional magnetic resonance imaging, resting-
22 state fluctuation amplitudes, cerebrovascular reactivity, cognitive impairment

23

24

25 **1. Background**

26

27 Frontotemporal dementia (FTD) encompasses a clinically heterogeneous group of
28 neurodegenerative diseases [1]. About a third of FTD cases present an autosomal dominant
29 family history, commonly caused by mutations in three genes: chromosome 9 open reading
30 frame 72 (*C9orf72*), progranulin (*GRN*), and microtubule-associated protein tau (*MAPT*) [2].
31 The study of prodromal FTD has identified neuropathological changes and biomarker
32 abnormalities decades before disease onset, including brain atrophy, reduced white matter
33 (WM) integrity, and disrupted functional connectivity, predominantly affecting the fronto-
34 temporo-parietal regions [3].

35

36 In addition to the tau and TDP-43-associated molecular pathologies, and secondary
37 inflammation, the pathophysiology of FTD involves cerebrovascular dysregulation [4]. It is
38 characterised by impairments in the brain's neurovascular unit (NVU) and blood-brain barrier
39 (BBB), with damaged endothelial cells, dysfunctional pericytes, and adjacent reactive
40 microglia, in people carrying FTD-related mutations [5, 6]. Furthermore, reductions in
41 cerebral blood flow (CBF) are found in both sporadic and genetic FTD, especially in frontal
42 cortex [7, 8]. The changes in cerebral blood flow correlate with impaired performance on
43 neuropsychological tests [9]. Combined with evidence of small-vessel pathology in autopsy-
44 confirmed cases with frontotemporal lobar degeneration (FTLD) [10], these findings suggest
45 a synergistic contribution of neurodegeneration and cerebrovascular impairment to the
46 pathophysiology of FTD [4].

47

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

48 An important aspect of cerebrovascular function is cerebrovascular reactivity (CVR).
49 CVR denotes the capacity of cerebral blood vessels to constrict or dilate in response to
50 physiological modulators, such as carbon dioxide concentration [11]. CVR regulates regional
51 blood flow via pH-dependent modulation of vascular smooth muscle tone [12-14]. It is
52 compromised by ageing [15], impaired endothelial function [16], and hypertension [17]. The
53 blood oxygenation-level dependent (BOLD) contrast reveals CVR alterations in Alzheimer's
54 disease (AD) and its prodrome [18, 19], leading to the hypothesis of comparable FTD-related
55 changes in CVR.

56

57 In this study, we investigated CVR in pre-symptomatic and symptomatic genetic FTD.
58 We used existing resting-state functional magnetic resonance imaging (rs-fMRI) data that are
59 based on exploiting naturally occurring fluctuations in carbon dioxide, induced by variations
60 in the cardiac and respiratory cycles, which moderate the BOLD signal [20, 21]. Resting-state
61 fluctuation amplitudes (RSFA) of the BOLD signal is a safe, scalable, and robust alternative
62 to the standard MRI approaches [22-24]. It is especially suitable for large-scale applications
63 with frail subjects, as it does not require hypercapnic gas inhalation, breath-holding, or
64 vasodilatory drugs [24-25], for a review, see Tsvetanov et al. (2021) [26]. RSFA has already
65 been used to assess differences in cerebrovascular and cardiovascular function associated
66 with ageing [27-29], cerebrovascular disorders [30], stroke [31], AD [32], as well as other
67 acute conditions that might heighten the risk of dementia [33].

68

69 The principal aim was to determine the CVR signature of pre-symptomatic and
70 symptomatic genetic FTD. A corollary was to assess CVR correlations with age and clinical
71 status. We predicted reductions in RSFA in at-risk mutation carriers compared to mutation-

72 negative family members; and that these differences would increase with disease progression
73 and relate to impaired cognitive performance.

74

75 **2. Methods**

76

77 **2.1. Participants**

78

79 Data were drawn from the fifth data freeze of the Genetic Frontotemporal Dementia
80 Initiative (GENFI, www.genfi.org), which included 31 research sites across Europe and
81 Canada. The study was approved by the institutional review boards at each site and written
82 informed consent was provided by participants. A total of 680 subjects were recruited
83 between January 30, 2012, and May 28, 2019, from families with a confirmed pathogenic
84 genetic mutation in *C9orf72*, *GRN*, or *MAPT*. They were either (i) symptomatic mutation
85 carriers, (ii) first-degree relatives of mutation carriers who were carrying a mutation, but did
86 not exhibit any symptoms (that is, pre-symptomatic), or (iii) mutation-negative family
87 members who served as a control group, termed non-carriers. Subjects were classified as
88 symptomatic if their clinician judged the presence of symptoms consistent with the diagnosis
89 of a progressive in nature degenerative disorder. Seven datasets were excluded due to motion-
90 related or other imaging artifacts (three symptomatic subjects with *C9orf72* mutations; three
91 pre-symptomatic *GRN* carriers, and one mutation-negative individual from a family with a
92 *GRN* mutation). This resulted in 673 usable fMRI scans from 124 symptomatic mutation
93 carriers (61 *C9orf72*, 40 *GRN*, 23 *MAPT*), 284 pre-symptomatic mutation carriers (107
94 *C9orf72*, 123 *GRN*, 54 *MAPT*), and 265 mutation-negative controls.

95

96

97 **2.2. Neurocognitive Assessment and Indices of Cognitive Function**

98

99 All participants underwent the standardised GENFI clinical evaluation consisting of
100 family and medical history, functional status, and physical examination in corroboration with
101 collateral history from a close contact. Subjects also completed a neuropsychological battery,
102 which included behavioural measures of cognitive function from the Uniform Data Set [34].
103 From this test battery, we used scores related to executive function (Digit Span Forwards and
104 Backwards from the Wechsler Memory Scale-Revised; Parts A and B of the Trail Making
105 Test; a Digit Symbol Task) and language (the short version of the Boston Naming Test;
106 Category Fluency (animals and combined)), as well as the Wechsler Abbreviated Scale of
107 Intelligence Block Design Task. More details on the recruitment procedure and clinical
108 assessment protocol can be found in Rohrer et al. (2015) [35].

109

110 As a proxy of cognitive function for subsequent statistical analysis, we used Principal
111 Component Analysis (PCA) to derive a latent variable from a set of cognitive performance
112 assessments. This enabled us to obtain a composite summary score characterising the
113 complexity of cognition whilst minimising the statistical problem of multiple comparisons
114 when investigating associations between genetic status, RSFA, and cognitive function. Thus,
115 we conducted PCA on subjects' performance measures from the Digit Span Forwards and
116 Backwards task, Parts A and B of the Trail Making Test, the Digit Symbol Task, Boston
117 Naming Test, Category Fluency (animals and combined), and Block Design Task to reduce
118 the dimensionality of cognitive function into one latent variable summarising the largest
119 portion of shared variance as the first principal component (PC 1). In cases of missing values
120 for some of the metrics, multivariate Markov Chain Monte Carlo imputation was performed

121 using the default settings of the multivariate imputation by chained equations (MICE) in R
122 [36].

123 **2.3. Image Acquisition and Pre-processing**

124

125 A three-dimensional (3D) structural MRI was obtained for each participant using a
126 T1-weighted Magnetic Prepared Rapid Gradient-Echo (MPRAGE) sequence on 3T scanners
127 available from various vendors. The scanning protocols at each GENFI site were optimised to
128 accommodate different manufacturers and field strengths [35]. The following acquisition
129 parameters were used: median isotropic resolution of 1 mm; repetition time (TR) of 2000 ms
130 (6.6 to 2400 ms); echo time (TE) of 2.9 ms (2.8 to 4.6 ms); inversion time (TI) of 8 ms (8 to 9
131 ms); field of view (FOV) of $256 \times 256 \times 208$ mm, with a minimum scanning time of at least
132 283 s (283 to 462 s).

133

134 The T1-weighted images were analysed using FSL pipelines [37, 38] and modules,
135 which called relevant functions from Statistical Parametric Mapping (SPM12, Wellcome 112
136 Department of Imaging Neuroscience, London, UK; www.fil.ion.ucl.ac.uk/spm) [39]. Native-
137 space segmentation of grey matter (GM), WM, and cerebrospinal fluid (CSF) tissue classes
138 and warps for normalisation to the Montreal Neurological Institute (MNI) template space
139 were estimated using FSL.

140

141 For resting-state fMRI measurements, Echo-planar imaging (EPI) data were obtained
142 with at least six minutes of scanning. Analogous imaging sequences were developed by the
143 GENFI Imaging Core team and used at each GENFI study site to account for different
144 scanner models and field strengths. EPI data were acquired over a minimum of 308 s (median
145 500 s) and had a median TR of 2500 ms (2200 to 2500 ms); TE of 30 ms; flip angle of 80 ms

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

146 (80 to 85 ms); in-plane resolution of 2.72×2.72 mm (2.72 - 3.50×2.72 - 3.25 mm); slice
147 thickness of 3.5 mm (2.72 to 3.5 mm). Participants were instructed to lie still with their eyes
148 closed. The initial six volumes were discarded to enable T1 equilibration. To quantify the
149 total motion for each participant, the root mean square volume-to-volume displacement was
150 computed using the approach of Jenkinson et al. (2002) [40].

151

152 The pre-processing was carried out using SPM12 running under MATLAB R2021b
153 (MathWorks, <https://uk.mathworks.com/>). The pre-processing steps comprised (i) spatial
154 realignment to correct for head motion and movement by distortion interactions, (ii) slice-
155 time correction to the middle slice, (iii) co-registration of the EPI to the participants' T1
156 anatomical scans. The normalisation parameters from the T1 image processing were then
157 applied to warp the functional images to MNI space. After that, the spatially normalised
158 images were smoothed with a Gaussian kernel of Full Width at Half Maximum (FWHM) of 8
159 mm to meet the lattice assumption of random field theory and account for residual inter-
160 participant structural variability.

161

162 Further processing procedures of the resting-state time-series for estimation of RSFA
163 involved the application of data-driven Independent Component Analysis (ICA) of single-
164 subject time-series denoising, with noise components selected and removed automatically
165 using *a priori* heuristics from the ICA-based Automatic Removal of Motion Artifacts
166 (AROMA) toolbox [41]. A general linear model (GLM) of the time-course at each voxel was
167 computed to further diminish any residual effects of noise confounds [42]. This included
168 linear and quadratic detrending of the fMRI signal, covarying out the motion parameters,
169 WM, and CSF signals, as well as their squares and first derivative [43], and a band-pass filter
170 (0.0078–0.01 Hz). Signals from WM and CSF were estimated for each volume from the

171 mean value of WM and CSF masks derived by thresholding SPM's corresponding tissue
172 probability maps at 0.75. The normalised variance (i.e., the temporal standard deviation (SD)
173 of the EPI signal amplitudes over the mean signal intensity) of these filtered time-series was
174 calculated on a voxel-wise basis to define RSFA.

175

176 **2.4. Indices of Cerebrovascular Function using RSFA**

177 ***2.4.1. Component-based Analysis***

178 To implement ICA, the pre-processed RSFA maps were decomposed into a set of
179 spatially independent sources using the Source-Based Morphometry toolbox [44] in the
180 Group ICA for fMRI Toolbox (GIFT; <http://mialab.mrn.org/software/gift>). Briefly, the
181 fastICA algorithm was applied after the optimal number of sources explaining the variance in
182 the data was identified by PCA with Minimum Description Length (MDL) criterion [45-47].
183 By combining PCA and ICA, one can decompose an n-by-m matrix of subjects-by-voxels
184 into a source matrix that maps independent components (ICs) to voxels (here referred to as
185 'IC maps'), and a mixing matrix that maps ICs to participants. The mixing matrix indicates
186 the degree to which an individual expresses a defined IC, known as the subject scores in the
187 mixing matrix. These scores were scaled to standardised values (z-scores) prior to between-
188 group analyses. The algorithmic and statistical reliability of the extracted components was
189 confirmed with 128 ICASSO (tool for investigating the reliability of ICA estimates by
190 clustering and visualisation) iterations [48]. Components showing high reliability across
191 multiple ICASSO iterations and comprising GM areas were deemed relevant and used in
192 subsequent analyses. This decision was based on the understanding that RSFA alterations
193 within GM areas are indicative of cerebrovascular reactivity (CVR) [29] and are shown to be
194 sensitive to cognitive function [49].

195

196

197 ***2.4.2. Voxel-based Univariate Analysis***

198 To understand the spatial distribution of CVR effects further, we performed a
199 sensitivity voxel-wise analysis on the RSFA maps using SPM12 in MATLAB. Clusters
200 where between-group RSFA differences were observed after correction for multiple testing
201 were used to define regions of interest (ROIs) for visualisation of effects across subjects.

202 **2.5. Statistical Analysis**

203 ***2.5.1. Descriptive Statistics***

204 Demographic characteristics were compared with SPSS (IBM Corp. Released 2021.
205 IBM SPSS Statistics for Windows, Version 29.0. Armonk, NY: IBM Corp). Due to unequal
206 sample sizes and variances between groups, Welch's ANOVA with Games-Howell post hoc
207 tests were employed for continuous data. Chi-square tests were used for categorical variables.
208 The significance level was defined as two-tailed, and the threshold was set at $p = 0.05$ for all
209 statistical procedures. In keeping with other GENFI reports, years to expected onset (EYO)
210 was defined as the difference between age at assessment and mean age at onset within the
211 family [35]. EYO is only provided for completeness and should be interpreted with caution,
212 noting that age of symptom onset cannot be reliably predicted based on family history in
213 *GRN* and *C9orf72* mutation carriers [50].

214 ***2.5.2. FTD-related Effects on Cerebrovascular Indices using RSFA***

215 Figure 1 gives a schematic overview of the processing pipeline and analytic approach
216 used in the study. RSFA differences between symptomatic and pre-symptomatic mutation

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

217 carriers (all genetic mutations combined) and non-carriers were examined on component-
218 based estimates of RSFA using multiple linear regression (MLR) with a robust fitting
219 algorithm (MATLAB function *fitlm.m*). In these models, the IC subject scores for each
220 component (termed $RSFA_{ICn}$, where n denotes the corresponding number of the selected
221 component) were entered as a dependent variable, with age, sex, and handedness as
222 covariates of no interest. Although scanning protocols within the cohort were designed to
223 maximise comparability across GENFI scanners and sites [35], distinct scanning platforms
224 can introduce systematic differences, potentially confounding true effects of interest [51].
225 Thus, scanning site was also inserted as a covariate of no interest.

226 We also tested the moderating effect of age on the case-control differences to explore
227 disease progression-related effects across genetic status groups, i.e., whether the age effect in
228 pre-symptomatic carriers would be stronger than the ‘normal’ age effect in non-carriers, due
229 to the development of latent, pre-symptomatic pathology. This enabled us to assess the
230 variance explained by genetic status beyond that accounted for by age and other covariates in
231 the MLR.

232 All models’ formulas were specified by Wilkinson’s notation, e.g., ‘ $RSFA_{IC} \sim I +$
233 $Genetic\ status * Age + Sex + Handedness + Scanning\ Site$ ’, providing a flexible way to test
234 for main effects of predictors of interest (i.e., genetic status and age) and their interaction
235 (genetic status*age), whilst adjusting the models for confounders of no interest (sex,
236 handedness, scanning site). To account for issues related to multiple testing, the overall
237 model fit was corrected using the Benjami-Hochberg procedure to control the false discovery
238 rate (FDR) at the 0.05 level. To better understand the nature of the observed effects in the
239 models surviving multiple comparisons, post hoc tests were performed across sub-groups of

240 interest (e.g., comparing non-carriers to symptomatic carriers, non-carriers to pre-
241 symptomatic carriers, and pre-symptomatic carriers to symptomatic carriers).

242 A sensitivity analysis was also conducted on the voxel-wise RSFA maps to further
243 explore the spatial distribution of CVR effects within the same statistical model ($RSFA_{Voxel} \sim$
244 $1 + Genetic\ status * Age + Sex + Handedness + Scanning\ Site$). This included the following
245 comparisons: (i) non-carriers versus symptomatic carriers, (ii) non-carriers versus pre-
246 symptomatic carriers, and (iii) pre-symptomatic carriers versus symptomatic carriers. The
247 primary cluster-forming threshold was set at $p = 0.05$. To correct for the multiple
248 comparisons problem inherent in mass univariate statistical analysis, we controlled for the
249 voxel-level FDR at $p < 0.05$. For transparency, in cases where results did not reach statistical
250 significance at FDR-level, the patterns are reported at an uncorrected level of $p < 0.01$ with a
251 minimum cluster size of 10 voxels. To visualise the nature of the observed effects and any
252 further between-group RSFA differences, ROIs were defined by selecting the voxels in an 8-
253 mm sphere at the peak of significant clusters from the MLR analysis. The average value
254 across voxels in each ROI was used to illustrate the relationship between RSFA and age for
255 different genetic status groups. The voxel-based level regions were labelled according to their
256 overlap with the Johns Hopkins University (JHU) atlas [52].

257 ***2.5.3. Behavioural Relevance of Cerebrovascular Impairment***

258 A secondary objective of this study was to evaluate the behavioural relevance of the
259 RSFA changes observed in the previous analyses for subjects' cognitive function. To assess
260 differences in cognitive performance scores between genetic status groups, we first carried
261 out a Kruskal-Wallis test, followed by Mann-Whitney post hoc tests. We subsequently ran a
262 further series of regression models where cognitive function, as represented by subjects'
263 scores for PC 1 from the PCA analysis, was the dependent variable. Independent variables

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

264 included the $RSFA_{IC}$ for each neurocognitively meaningful component (see Methods, 2.4.
265 Indices of Cerebrovascular Function using RSFA, sub-section 2.4.1. Component-based
266 Analysis), and its interaction with genetic status, to test whether the relationship between
267 cognitive performance and RSFA levels would vary across genetic status groups. Covariates
268 of no interest were age, sex, handedness, and scanning site.

269 Models' formulas, as specified by Wilkinson's notation, took the form: ' $Cognition_{PCI}$
270 $\sim I + Genetic\ status * RSFA_{IC/Voxel} + Age + Sex + Handedness + Scanning\ Site$ '. FDR
271 correction was applied ($FDR < 0.05$) and post hoc tests across sub-groups of interest were
272 conducted in cases where main effects were found (Figure 1).

273 **3. Results**

274 **3.1. Demographics**

275 Demographic characteristics of the sample and descriptive statistics are provided in
276 Table 1. Mutation-negative family members and pre-symptomatic mutation carriers were
277 younger than symptomatic carriers (mean difference between non-carriers and symptomatic
278 carriers was 16.68 years ($p < 0.001$) and 18.71 years between pre-symptomatic carriers and
279 symptomatic carriers, respectively, ($p < 0.001$)). The pre-symptomatic carriers were age-
280 matched to non-carriers ($p = 0.132$). There was a higher proportion of females, relative to
281 males, in asymptomatic individuals (non-carriers and pre-symptomatic carriers) compared to
282 symptomatic carriers, and these two groups had also spent more years in education. No
283 significant differences were observed between the non-carriers and pre-symptomatic carriers
284 for any of the remaining demographic variables.

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

Table 1. Demographic information of participants included in the analysis, grouped by genetic status as non-carriers, pre-symptomatic carriers, and symptomatic carriers

Demographics	Sample	NC	PSC	SC	Group comparison, <i>P</i> value*			
					Sample	NC vs SC	PSC vs SC	NC vs PSC
Total N	673	265 (39.38)	284 (42.2)	124 (18.42)				
Family mutation								.126
<i>C9orf72</i>	264 (39.23)		107	61				
<i>GRN</i>	276 (41.01)		123	40				
<i>MAPT</i>	133 (19.76)		54	23				
Age (years)	48.17±13.43	45.95±13.09	43.93±11.4	62.64±7.43	<.001	<.001	<.001	.132
Sex ratio f:m	371:302	153:112	165:119	53:71	.009	.006	.004	.931
Estimated years from onset	-10.62±13.40	-13.21±13.47	-14.30±11.63	3.32±6.24	<.001	<.001	<.001	.569
Education (years)	14.18±3.45	14.51±3.35	14.50±3.36	12.72±3.53	<.001	<.001	<.001	.998

285 Values indicate count (percentage) or mean ± standard deviation.

286 **P* values are the result of F test or χ^2 test as appropriate. Bold numbers denote statistical significance at $p < 0.05$
 287 level.

288 Abbreviations: *C9orf72*, chromosome 9 open reading frame 72; *GRN*, progranulin; *MAPT*, microtubule-
 289 associated protein tau. NC, non-carrier; PSC, pre-symptomatic mutation carrier; SC, symptomatic mutation
 290 carrier. f, female; m, male.

291

292

293

294

295 **3.2. Regional Differences in RSFA based on Independent Component Analysis**

296 Applying ICA to the RSFA data yielded 24 components based on the MDL criterion.
297 The spatial patterns indicated signal origins within GM regions, as well as origins associated
298 with vascular aetiology, CSF, or other non-physiological factors (Appendix A, Figure A.1). A
299 total of 20 components were excluded from further analysis; these included non-GM
300 components proximal to vascular and CSF territories or components exhibiting characteristics
301 of physiological noise signals (Appendix A, Table A.1). Additionally, GM components that
302 did not survive correction for multiple comparisons were also classified as irrelevant. The
303 overall model fit of four GM components remained significant after FDR correction (Figure
304 2). These components included strong contributions of voxels within the posterior cingulate
305 cortex (PCC)/precuneus (IC 4), posterior association and parieto-occipital association areas,
306 more pronounced on the right side (IC 17), right and left lateral prefrontal cortex (IC 21 and
307 IC 23, respectively). A tendency of FTD-dependent decrease in RSFA was found in
308 symptomatic and pre-symptomatic carriers, compared to non-carriers, for all components, but
309 only reached statistical significance for component IC 21. Post hoc tests revealed that this
310 effect was driven by differences between the non-carriers and symptomatic mutation carriers,
311 as well as between the pre-symptomatic and symptomatic carriers. In addition, in analyses
312 across the entire sample, a significant main effect of genetic status x age interaction was
313 shown for components IC 17, IC 21, and IC 23, whereby symptomatic carriers showed the
314 most pronounced age-related RSFA reductions, followed by the presymptomatic carriers, and
315 then mutation-negative individuals. This suggests a greater age-related RSFA decline in at-
316 risk or affected mutation carriers relative to non-carriers, which likely further exacerbates
317 downstream effects of the disease over time, as indicated by the steeper negative slopes of the
318 regression lines observed in these groups. Spatial maps of these components, accompanied by
319 scatter plots showing IC subject score values in relation to age and genetic status group, are

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

320 presented in Figure 2. Table 2 summarises the numerical output of the MLR models
321 conducted on the RSFA-IC subject scores for these GM components across the entire sample.
322 The output of post hoc tests across sub-groups of interest for this analysis is provided in
323 Appendix A, Table A.2.

324 ICA also revealed components with spatial distribution originating from large blood
325 vessels and CSF (Appendix A, Figure A.1). For example, components 2 and 3 reflected
326 signals from the fluid-filled ventricles and cerebral aqueduct. Component 11 indicated signals
327 originating close to sites of venous drainage, including superior and inferior sagittal sinus,
328 and transverse sinuses. Other vascular components comprised territories of major blood
329 vessels, including the Circle of Willis, internal carotid artery, anterior cerebral artery, and
330 middle cerebral artery. These vascular and CSF components tended to display higher subject
331 scores in older (symptomatic) individuals, reflecting differences in vascular health and other
332 physiological factors [26, 28, 29].

333

334

335

336

337

338

339

340

341

342

343

344

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

345

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

Table 2. Multiple regression analysis results of independent component (IC) subject loadings from independent component analysis (model ' $RSFA_{IC} \sim 1 + Genetic\ status * Age + Sex + Handedness + Scanning\ Site$ ')

Predictor of interest	Model Adjusted R ²	β	T	Uncorrected P	FDR- corrected P*
IC 4 – Posterior cingulate cortex/precuneus					
	0.62				
Age		-0.09	-3.59	<.001	.001
Genetic status		-0.05	-1.77	.078	.124
Genetic status*Age		-0.05	-2.00	.046	.085
IC 17 – Posterior parietal association areas					
	0.54				
Age		-0.13	-4.27	<.001	<.001
Genetic status		-0.06	-1.80	.072	.098
Genetic status*Age		-0.06	-2.17	.030	.048
IC 21 – Right lateral prefrontal cortex					
	0.44				
Age		-0.11	-3.33	<.001	.004
Genetic status		-0.10	-2.68	.008	.021
Genetic status*Age		-0.07	-2.31	.021	.046
IC 23 – Left lateral prefrontal cortex					
	0.49				
Age		-0.22	-7.22	<.001	<.001
Genetic status		-0.06	-1.87	.062	.168
Genetic status*Age		-0.08	-2.52	.012	.044

RSFA differences across groups of interest following robust multiple linear regression analysis on component-based RSFA maps.

Estimated regression parameters, t values, and p values are shown for main effects across the entire sample. Outcomes of interest are the RSFA-IC loadings associated with ICA components within GM regions where case-control differences are found. Models are adjusted for sex, handedness, and scanning site.

* P values are FDR-corrected at the 0.05 level in comparisons across the whole sample (all genetic status groups combined). Bold numbers indicate that p values are statistically significant.

346

347

348 **3.3. Spatial Distribution and Voxel-wise Univariate Differences in RSFA**

349 Overall, voxel-based analysis results were consistent with component-based analysis,
350 particularly in frontal cortical regions (**Error! Reference source not found.** 3). Group-level
351 analysis across all genetic groups revealed a consistent pattern of RSFA decreases in frontal
352 midline areas, cuneus, precuneus, and cerebellum. Moreover, a comparable tendency
353 emerged in relation to disease progression informed by the interaction between genetic status
354 and age. Specifically, the inverse relationship between RSFA and age was stronger across the
355 spectrum from non-carriers to pre-symptomatic carriers to symptomatic carriers. The spatial
356 distribution of voxel-based RSFA effects, including four representative ROIs where the
357 strongest effects were demonstrated, is illustrated in Figure 3. The output from the MLR
358 models performed on the RSFA-ROI estimates across the entire sample is provided in Table
359 3. The results of post hoc tests across sub-groups of interest conducted subsequently are
360 provided in Appendix A, Table A.3.

361

362

363

364

365

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

Table 3. Multiple regression analysis results following voxel-based region of interest analysis (model ' $RSFA_{Voxel} \sim I + Genetic\ Status * Age + Sex + Handedness + Scanning\ Site$ ')

Predictor of interest	Model Adjusted R ²	β	T	Uncorrected P	FDR- corrected P*
Left middle frontal gyrus	0.23				
Age		-0.09	-2.51	.012	.034
Genetic status		-0.14	-3.25	.001	.005
Genetic status*Age		-0.16	-4.28	<.001	<.001
Right middle frontal gyrus	0.25				
Age		-0.13	-3.72	<.001	.002
Genetic status		-0.15	-3.72	<.001	.002
Genetic status*Age		-0.08	-2.25	.025	.041
Left superior frontal gyrus	0.17				
Age		-0.05	-1.37	.170	.320
Genetic status		-0.19	-4.45	<.001	<.001
Genetic status*Age		-0.08	-2.16	.031	.093
Right superior frontal gyrus	0.26				
Age		-0.10	-2.79	.005	.013
Genetic status		-0.17	-4.09	<.001	<.001
Genetic status*Age		0.06	-1.54	.123	.148

RSFA differences across groups of interest following robust multiple linear regression analysis in several representative ROIs based on voxel-wise univariate analysis on RSFA maps. Estimated regression parameters, t values, and p values are shown for main effects across the entire sample. Outcomes of interest are the RSFA-ROI values associated with each ROI where case-control differences are found. Models are adjusted for sex, handedness, and scanning site.

*P values are FDR-corrected at the 0.05 level across the whole sample (all genetic status groups combined). Bold numbers indicate

that p values are statistically significant.

366

367 Regarding genetic status effects on voxel-wise RSFA, there were several clusters
368 where symptomatic carriers exhibited significant reductions, compared to non-carriers,
369 including bilateral middle frontal gyrus (MFG), right superior frontal gyrus (SFG), right
370 superior temporal gyrus (STG), and bilateral PCC. Symptomatic carriers also displayed
371 greater age-related RSFA decline in the same areas, as well as in the left SFG, left dorsal
372 anterior cingulate cortex (ACC), and right insula. Similar clusters displayed RSFA decreases
373 when symptomatic carriers were compared to pre-symptomatic counterparts. In contrast, the
374 differences between pre-symptomatic carriers and non-carriers did not reach statistical
375 significance at FDR-levels. However, pre-symptomatic carriers showed a tendency for
376 reduced RSFA in posterior parietal cortex and more pronounced age-related decline in RSFA
377 over the parietal and frontal cortex compared to non-carriers, similar to the trend observed in
378 the symptomatic group. A detailed description of the anatomical localisation of the voxel-
379 based analysis derived clusters where RSFA differences were noted can be consulted in
380 Appendix A, Table A.4.

381 Finally, to evaluate differences in RSFA values across different gene mutations, we
382 compared RSFA-IC loadings and RSFA-ROI estimates in mutation carriers stratified by gene
383 mutation using MLR. No between-group differences were detected based on mutated gene in
384 any of the ICs or ROIs where differences between asymptomatic and symptomatic carriers
385 were encountered in the previous analyses (data are shown in Appendix A, Table A.5).

386

387

388

389 **3.4. Relationship between RSFA and Cognition**

390 PCA analysis estimated PC 1 to explain approximately 62 % of the variance across
391 the nine measures of cognitive performance, PC 2 – 9 %, and PC 3 – 7 %. We therefore focus
392 on the relationship between genetic status, RSFA, and PC 1 as a proxy for cognitive function.
393 The cognitive variables that loaded most prominently on this component included the Trail
394 Making Test Parts A and B, Digit Symbol Task, and Verbal Fluency, suggesting that PC 1
395 captures most strongly the cognitive domain of executive function. More detailed information
396 about each PC, with explained variance and corresponding coefficients, is provided in
397 Appendix A, Table A.6, and Figures A.2 and A.3, respectively. Kruskal-Wallis test showed a
398 statistically significant difference in PC 1 subject scores between genetic status groups ($\chi^2(2)$
399 = 256.02, $p < 0.001$). As anticipated, post hoc Mann-Whitney tests confirmed significantly
400 lower PC 1 subject scores, indicative of lower cognitive function, in symptomatic carriers
401 compared to both pre-symptomatic carriers ($U = 1461$, $p < 0.001$) and non-carriers ($U =$
402 1182, $p < 0.001$). No significant difference was observed between pre-symptomatic carriers
403 and non-carriers ($U = 36\ 318$, $p = 0.480$).

404

405 Further regression analysis revealed a positive relationship between RSFA and
406 cognitive function, specifically in IC 23, suggesting that individuals with higher CVR levels
407 in left PFC performed better overall on a range of cognitive tests. In addition, a genetic status
408 x RSFA interaction was observed in left PFC (IC 23), as well as in posterior parietal
409 association areas (IC 17) and right lateral PFC (IC 21). The interaction effects, presented in
410 Figure 4, highlight a stronger positive relationship between RSFA and cognitive function in
411 mutation carriers, particularly in symptomatic individuals, than in non-carriers. ROIs analysis
412 was overall consistent with component-based analysis (Figure 4). The output from the MLR

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

- 413 models assessing cognitive function in relation to RSFA indices across the sample and sub-
- 414 groups of interest can be consulted in Table 4.

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

Table 4. Multiple regression analysis results of cognition as a function of RSFA (model ' $Cognition_{PCI} \sim I + Genetic\ status * RSFA_{IC/Voxel} + Age + Sex + Handedness + Scanning\ Site$ ')

Predictor	Model	Sample			NC versus SC			PSC versus SC			NC versus PSC		
		Adjusted R ²	β	T	P*	β	T	P*	β	T	P*	β	T
<i>ICs based on Independent Component Analysis</i>													
IC 4 – Posterior cingulate cortex/precuneus													
		0.52											
Age		-0.43	-14.10	<.001	-0.23	-6.36	<.001	-0.30	-7.69	<.001	-0.37	-9.45	<.001
Genetic status		-0.40	-13.07	<.001	-0.68	-18.09	<.001	-0.61	-15.28	<.001	-0.01	-0.19	.851
RSFA		0.04	0.80	.600									
Genetic status*RSFA		0.04	1.43	.339									
IC 17 – Posterior association areas													
		0.52											
Age		-0.44	-14.23	<.001	-0.23	-6.46	<.001	-0.30	-7.67	<.001	-0.37	-9.38	<.001
Genetic status		-0.40	-13.05	<.001	-0.68	18.21	<.001	-0.61	-15.28	<.001	-0.01	-0.29	.769
RSFA		-0.01	-0.04	.980									
Genetic status*RSFA		-0.08	2.84	.029	0.04	1.33	.183	0.02	0.53	.600	0.07	1.77	.078
IC 21 – Right lateral prefrontal cortex													
		0.53											
Age		-0.43	-14.08	<.001	-0.23	-6.55	<.001	-0.30	-7.76	<.001	-0.37	-9.40	<.001
Genetic status		-0.39	-12.61	<.001	-0.67	-17.74	<.001	-0.60	-14.73	<.001	-0.01	-0.16	.869
RSFA		0.08	2.06	.124									
Genetic status*RSFA		0.09	3.40	.008	0.05	1.91	.057	0.02	0.64	.523	0.05	1.26	.207

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

IC 23 – Left lateral prefrontal cortex

	0.52											
Age	-0.40	-12.85	<.001	0.22	-6.05	<.001	-0.29	-7.24	<.001	-0.36	-8.92	<.001
Genetic status	-0.38	-12.33	<.001	0.67	-17.51	<.001	-0.59	-14.28	<.001	-0.01	-0.19	.846
RSFA	0.11	2.88	.029	0.07	1.69	.091	0.07	1.76	.079	0.07	1.38	.169
Genetic status*RSFA	0.08	2.83	.030	0.01	0.21	.831	0.03	1.06	.289	-0.04	-0.90	.367

ROIs based on Voxel-wise Analysis

Left middle frontal gyrus

	0.57											
Age	-0.38	-12.92	<.001	-0.20	-6.01	<.001	-0.28	-7.58	<.001	-0.36	-9.17	<.001
Genetic status	-0.35	-11.51	<.001	-0.60	-15.18	<.001	0.53	-12.82	<.001	-0.003	-0.07	.944
RSFA	0.13	4.42	<.001	0.10	2.95	.003	0.14	4.35	<.001	-0.03	-0.82	.412
Genetic status*RSFA	0.23	8.02	<.001	0.22	6.60	<.001	0.16	4.84	<.001	0.07	1.73	.085

Right middle frontal gyrus

	0.54											
Age	-0.41	-13.76	<.001	-0.24	-6.61	<.001	-0.30	-7.63	<.001	-0.37	-9.26	<.001
Genetic status	-0.37	-11.84	<.001	-0.64	-15.63	<.001	-0.58	-14.04	<.001	-0.003	-0.07	.943
RSFA	0.11	3.59	.003	0.07	2.11	.036	0.07	2.15	.032	0.05	1.12	.261
Genetic status*RSFA	0.15	5.25	<.001	0.07	2.06	.040	0.04	1.30	.195	0.05	1.23	.220

Left superior frontal gyrus

	0.54											
Age	-0.42	-13.88	<.001	-0.23	-6.47	<.001	-0.30	-7.98	<.001	-0.37	-9.36	<.001
Genetic status	-0.38	-12.10	<.001	-0.64	-16.37	<.001	-0.58	-13.94	<.001	-0.01	-0.17	.861
RSFA	0.08	2.49	.054	0.06	1.85	.065	0.05	1.67	.096	-0.04	-0.85	.398

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

Genetic status*RSFA	0.14	4.83	<.001	0.12	3.57	<.001	0.09	2.99	.003	0.002	0.06	.951
Right superior frontal gyrus												
	0.54											
Age	-0.42	-14.05	<.001	-0.23	-6.59	<.001	-0.30	-7.72	<.001	-0.37	-9.43	<.001
Genetic status	-0.39	-12.64	<.001	-0.67	-17.30	<.001	-0.60	-14.64	<.001	-0.01	-0.29	.769
RSFA	0.03	0.82	.610									
Genetic status*RSFA	0.15	5.29	<.001	0.09	2.91	.004	0.04	1.28	.201	0.07	1.90	.058

Cognitive function differences as a function of RSFA and genetic status following robust multiple linear regression analysis in ICA-based components (top panel) and several representative ROIs based on voxel-wise univariate analysis on RSFA maps (bottom panel). Cognitive function is represented by subjects' loading values for PC 1 following PCA on nine cognitive measures. Estimated regression parameters, t values, and *p* values are shown for main effects across the entire sample and sub-groups of interest where relevant. Models are adjusted for age, sex, handedness, and scanning site.

**P*-values are FDR-corrected at the 0.05 level across the whole sample (all genetic status groups combined). Bold numbers indicate that *p* values are statistically significant.

Abbreviations: NC, non-carrier; PSC, pre-symptomatic mutation carrier; SC, symptomatic mutation carrier.

415

416

4. Discussion

417

418

419

420

421

422

423

We confirmed that cerebrovascular function, as measured by the resting-state fluctuation amplitudes, is reduced by mutations associated with frontotemporal dementia even in the long pre-symptomatic period. The RSFA differences worsened with disease progression and correlated with cognition in mutation carriers, over and above the effects of ageing. We propose that cerebrovascular dysfunction in genetic FTD represents an early dysregulated feature in the disease's pathophysiology, which may interact with neurodegenerative changes.

424

425 **4.1. Regional Distribution of Cerebrovascular Reactivity Impairment in FTD**

426 Progressive reductions in RSFA were observed in mutation carriers versus non-
427 carriers in ventromedial and dorsolateral prefrontal cortical areas, cingulate and parietal
428 cortex. Comparable CVR decreases using the RSFA approach are reported in healthy ageing
429 and acute conditions of microvascular impairment, particularly in prefrontal and superior-
430 parietal cortical areas [28, 29, 33] that are vulnerable to lower cerebral blood flow [26, 53,
431 54] and the principal FTD-specific pathological burden. This regional vulnerability aligns
432 with the observation of abnormal vasoreactivity in the default mode network (DMN) in AD
433 [18, 19, 32, 55]. In genetic FTD, we found consistent CVR reductions in frontal cortex,
434 anterior cingulate, and insula – regions accordant with atrophy [2, 35, 56, 57] and cerebral
435 perfusion decreases [8, 9, 58] in pre-symptomatic and symptomatic carriers. These areas are
436 part of the salience network, which underlies cognitive, sensory, and affective regulation,
437 language, motor control, and social conduct, each functionally impaired in symptomatic FTD
438 [59, 60].

439 We argue that the observed cerebrovascular dysfunction in FTD represents an early
440 dysregulated pathophysiology, interacting with regional neurodegenerative changes, as
441 postulated in AD [61-63]. Potential causes for the CVR decreases include pH dysregulation
442 and impaired modulation of nitric oxide, which may diminish endothelium-dependent dilator
443 responses and the dynamic range of the BOLD signal [16, 64, 65]. Alterations in the
444 neurovascular unit, including dysfunctional vascular endothelium, hypercontractile vascular
445 smooth muscle cells [62], depleted pericytes [5], and activated microglia [6] have been
446 documented in familial FTD. Given the close interrelatedness between neurons and cerebral
447 microvessels, such changes likely compromise the function of the blood-brain barrier,

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

448 diminish brain perfusion, and trigger the aggregation of aberrant circulating proteins and
449 secretion of pro-inflammatory factors, accelerating neurodegeneration [61, 62]. These
450 findings underscore the need for further research to discern the relationship between
451 cerebrovascular dysfunction and neurodegenerative processes in FTD and other
452 neurodegenerative pathologies.

453 While the RSFA variances in inferior frontal, parietal, and precuneus (IC 4 and IC 17)
454 accord with FTD-related hypoperfusion and atrophy profiles, the notable RSFA reductions in
455 dorsolateral prefrontal cortex (IC 21 and IC 23) are intriguing. These regions are not
456 commonly associated with hypoperfusion and atrophy in early FTD. This discrepancy implies
457 a shared pathway leading to CVR impairment, hypoperfusion, and atrophy in inferior frontal
458 and parietal regions. However, the mechanisms underlying the distinct CVR effects in
459 dorsolateral frontal regions in FTD and the processes that interact with these changes prompt
460 further investigation.

461 Such CVR alterations develop in the long pre-symptomatic window and increase with
462 age in mutation carriers faster than in non-carriers. This suggests less effective dampening of
463 arterial pressure pulsations through the vascular tree (i.e., diminished Windkessel effect)
464 owing to increased arterial stiffening [26], which could influence the BOLD signal
465 fluctuation in neighbouring tissue, including WM and CSF [66]. Such an interpretation
466 supports previously reported RSFA increases near cerebral ventricles and vascular territories,
467 and likely reflects the cardiovascular contribution to the RSFA signal in ageing [26, 28]. It is
468 also plausible that the RSFA signal in ICA-identified regions captures multiple sources with
469 different aetiology, particularly at boundaries of large vessels and adjacent perivascular
470 space, that may exhibit different spontaneous brain activity at rest [67]. The latter illustrates
471 the challenge of dissociating spatially overlapping sources of signal using univariate methods

472 and motivate the use of data-driven and multimodal approaches [68], as underscored by our
473 findings.

474 Although we observed diminished CVR in signature FTD frontal and parietal areas,
475 no substantial RSFA decreases in temporal regions were found. Given the involvement of the
476 temporal lobes, especially in *MAPT* mutations [8, 35, 56], this result may be due to type II
477 error or the much smaller size of the *MAPT* group than the *C9orf72* and *GRN* groups. We
478 compared the RSFA-IC loadings and RSFA-ROI estimates based on gene mutation but did
479 not discover any significant between-group effects. This null result may be caused by small
480 and unbalanced sub-groups per mutated gene but may also imply true commonalities in the
481 vascular pathology downstream of the mutations' molecular pathology. Previous
482 neuroimaging studies have revealed gene mutation-specific brain changes in FTD [56, 69].
483 The CVR changes in frontal regions may reflect distinct mechanisms from the atrophy and
484 perfusion alterations in temporal areas discovered in earlier FTD investigations. In line with
485 this assumption, different CVR and CBF patterns have been documented in AD, with CVR
486 deficits in prefrontal, anterior cingulate, and insular cortex proposed as direct indicators of
487 vascular dysfunction, and CBF decreases in temporal and parietal cortices attributed to
488 atrophy-related lower metabolic demand [55]. Our results could denote a similar mechanism
489 whereby CVR impairment contributes to FTD disease progression both independently and
490 conjointly with other pathophysiological processes.

491 **4.2. Relationship between Cerebrovascular Impairment and Cognition**

492 As a secondary objective, we examined the behavioural relevance of CVR alterations
493 and found a relationship between RSFA reductions in mutation carriers and diminished
494 cognitive function. This broadly confirmed the link between CVR decreases and impaired
495 overall cognitive status, as previously shown in mild cognitive impairment (MCI) and AD

496 [19], and conditions that may alter the risk of dementia [33]. Furthermore, CVR impairment
497 predicts global cognitive performance independently of AD pathological markers, such as
498 CSF-derived β -amyloid42 ($A\beta$ 42) and tau in healthy elderly and subjects with mixed
499 Alzheimer's and vascular cognitive impairment and dementia [70].

500 We observed an association between higher RSFA and better global cognitive
501 function, especially in symptomatic mutation carriers, pronounced in prefrontal cortical areas
502 – an effect that remained after adjusting for age and disease progression effects. This accords
503 with evidence from ageing, AD, and FTD studies about the increased dependence of
504 successful cognition on precisely regulated function within and between large-scale brain
505 networks [71-74]. Furthermore, progressively stronger coupling between function and
506 cognition is described in pre-symptomatic mutation carriers from the GENFI cohort as they
507 approached their expected age of disease onset, in the absence of differences in cognitive
508 performance relative to non-carriers [57]. Therefore, our observations support previous
509 research and suggest that CVR may benefit cognition in FTD at-risk individuals.

510 CVR impairment in DMN regions did not correlate with cognition. This implies that
511 the CVR changes in default network may not relate directly to the neuropathological
512 processes or disease progression and may instead be influenced by other factors that
513 modulate CVR, such as medications, as shown in ageing [75]. The nature of default network
514 CVR changes and its implications for DMN suppression in neurodegeneration remains to be
515 fully defined. However, findings on default network from fMRI BOLD studies should not be
516 interpreted independently of cerebrovascular variations induced by physiological modulators
517 [26].

518 **4.3. Methodological Considerations and Future Directions**

519 Several methodological remarks warrant consideration. Firstly, our design was cross-
520 sectional, so any causal inferences about the associations remain to be addressed in
521 longitudinal analyses. Second, several of the described effects only approached statistical
522 significance, which could imply that the FDR multiple comparison correction was
523 conservative. In the voxel-based analysis, no differences emerged between pre-symptomatic
524 carriers and non-carriers. Despite that, the distribution of CVR effects in pre-symptomatic
525 carriers resembled that of symptomatic cases, highlighting the vulnerability of the middle
526 frontal and posterior cortical areas. Third, we recognise that RSFA-CVR is just one measure
527 of cerebrovascular health. Previous examinations using the RSFA method have documented
528 that RSFA relates to CBF effects, white matter hyperintensities (WMHs), and cardiovascular
529 factors [26]. Thus, future investigations in the GENFI sample should clarify which vascular
530 factors drive the RSFA changes reported here by adopting other means to quantify
531 cerebrovascular function, such as resting arterial-spin labelling (ASL)-CBF and WMH
532 burden on MRI. Another avenue for future efforts is to complement current analyses with
533 estimates of functional and WM integrity, as well as CSF and blood markers in relation to
534 cognitive decline [29] in a multi-modal manner [68, 75]. On a clinical level, using integrative
535 approaches to uncover protective factors in prodromal stages of disease may improve
536 prognosis and inform stratification procedures, future triallists, patients, and carers.

537 **5. Concluding Remarks**

538 Using the RSFA approach, we found CVR alterations in pre-symptomatic and
539 symptomatic FTD with a pronounced frontal cortical predilection, concordant across
540 component-based and voxel-level analyses. We also showed that higher CVR yields a
541 cognitive benefit, especially in subjects at elevated FTD risk. These results demonstrate that
542 RSFA can be used as a safe, tolerable, and clinically informative signal that can aid the

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

543 quantification of cerebrovascular health in large-scale population studies among frail
544 participants. We suggest that there is a vascular contribution that interacts with FTD
545 pathology in driving disease expression and progression. Cerebrovascular health may be a
546 potential target for biomarker identification and a modifiable factor, to mitigate against
547 clinical deterioration in people at genetic risk of frontotemporal dementia.

548

549 **Acknowledgements**

550 The authors would like to thank the participant volunteers and their families for
551 their contribution to this research. We also thank Hamid Azimi for technical assistance,
552 as well as all radiographers/technicians and research nurses from all research sites
553 involved in this study for their invaluable support in data acquisition.

554

555 **Declaration of Interest**

556 All authors have no conflicts of interest. Untreated to this there are several
557 disclosures.

558

559 **Sources of Funding**

560 K.A.T. was supported by Fellowship awards from the Guarantors of Brain
561 (G101149) and Alzheimer's Society, UK (grant number 602). J.B.R. has received
562 funding from the Wellcome Trust (103838; 220258) and is supported by the Cambridge
563 University Centre for Frontotemporal Dementia, the Medical Research Council
564 (MC_UU_00030/14; MR/T033371/1) and the National Institute for Health Research
565 Cambridge Biomedical Research Centre (NIHR203312: BRC-1215-20014) and the Holt
566 Fellowship. The views expressed are those of the authors and not necessarily those of
567 the NIHR or the Department of Health and Social Care. J.C.V.S., L.C.J. and H.S. are
568 supported by the Dioraphte Foundation grant 09-02-03-00, Association for
569 Frontotemporal Dementias Research Grant 2009, Netherlands Organisation for
570 Scientific Research grant HCM1 056-13-018, ZonMw Memorabel (Deltaplan Dementie,
571 project number 733 051 042), ZonMw Onderzoeksprogramma Dementie (YOD-
572 INCLUDED, project number 10510032120002), EU Joint Programme-
573 Neurodegenerative Disease Research-GENFI-PROX, Alzheimer Nederland and the

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

574 Bluefield Project. R.S-V. is supported by Alzheimer’s Research UK Clinical Research
575 Training Fellowship (ARUK-CRF2017B-2) and has received funding from Fundació
576 Marató de TV3, Spain (grant no. 20143810). C.G. received funding from EU Joint
577 Programme-Neurodegenerative Disease Research-Prefrontals Vetenskapsrådet Dnr 529-
578 2014-7504, EU Joint Programme-Neurodegenerative Disease Research-GENFI-PROX,
579 Vetenskapsrådet 2019-0224, Vetenskapsrådet 2015-02926, Vetenskapsrådet 2018-
580 02754, the Swedish FTD Initiative-Schörling Foundation, Alzheimer Foundation, Brain
581 Foundation, Dementia Foundation and Region Stockholm ALF-project. D.G. received
582 support from the EU Joint Programme-Neurodegenerative Disease Research and the
583 Italian Ministry of Health (PreFrontALS) grant 733051042. R.V. has received funding
584 from the Mady Browaeys Fund for Research into Frontotemporal Dementia. J.L.
585 received funding for this work by the Deutsche Forschungsgemeinschaft German
586 Research Foundation under Germany’s Excellence Strategy within the framework of the
587 Munich Cluster for Systems Neurology (EXC 2145 SyNergy—ID 390857198). M.O.
588 has received funding from Germany’s Federal Ministry of Education and Research
589 (BMBF). E.F. has received funding from a Canadian Institute of Health Research grant
590 #327387. M.M. has received funding from a Canadian Institute of Health Research
591 operating grant and the Weston Brain Institute and Ontario Brain Institute. F.M. is
592 supported by the Tau Consortium and has received funding from the Carlos III Health
593 Institute (PI19/01637). J.D.R. is supported by the Bluefield Project and the National
594 Institute for Health and Care Research University College London Hospitals Biomedical
595 Research Centre and has received funding from an MRC Clinician Scientist Fellowship
596 (MR/M008525/1) and a Miriam Marks Brain Research UK Senior Fellowship. Several
597 authors of this publication (J.C.V.S., M.S., R.V., A.d.M., M.O., R.V., J.D.R.) are
598 members of the European Reference Network for Rare Neurological Diseases (ERN-

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

599 RND) - Project ID No 739510. This work was also supported by the EU Joint
600 Programme-Neurodegenerative Disease Research GENFI-PROX grant [2019-02248; to
601 J.D.R., M.O., B.B., C.G., J.C.V.S. and M.S. For the purpose of open access, the author
602 has applied a CC BY public copyright licence to any Author Accepted Manuscript
603 version arising from this submission.

604

605

606 JBR is a non-remunerated trustee of the Guarantors of Brain, Darwin College,
607 and the PSP Association; he provides consultancy to Alzheimer Research UK,
608 Asceneuron, Alector, Biogen, CuraSen, CumulusNeuro, UCB, SV Health, and Wave,
609 and has research grants from AZ-Medimmune, Janssen, Lilly as industry partners in the
610 Dementias Platform UK.

611

612

613

614

615

616

617

618

619

620

621

622

623

624

625

626

627

628

629

630

631

632

633

634

635

636

References:

637

1. Coyle-Gilchrist IT, Dick KM, Patterson K, Vázquez Rodríguez P, Wehmann E, Wilcox A, Lansdall CJ, Dawson KE, Wiggins J, Mead S, Brayne C. Prevalence, characteristics, and survival of frontotemporal lobar degeneration syndromes.

638

639

640

Neurology. 2016 May 3;86(18):1736-43. [https://doi.org/10.1007/S00415-019-](https://doi.org/10.1007/S00415-019-09363-4)

641

[09363-4](https://doi.org/10.1007/S00415-019-09363-4)

642

2. Greaves CV, Rohrer JD. An update on genetic frontotemporal dementia. Journal

643

of neurology. 2019 Aug 1;266(8):2075-86.

644

<https://doi.org/10.1007/s00415-019-09363-4>

645

3. Meeter LH, Kaat LD, Rohrer JD, Van Swieten JC. Imaging and fluid biomarkers in frontotemporal dementia. Nature Reviews Neurology. 2017 Jul;13(7):406-19.

646

647

<https://doi.org/10.1038/nrneurol.2017.75>

648

4. Raz L, Knoefel J, Bhaskar K. The neuropathology and cerebrovascular mechanisms of dementia. Journal of Cerebral Blood Flow & Metabolism. 2016

649

650

Jan;36(1):172-86. <https://doi.org/10.1038/jcbfm.2015.164>

651

5. Gerrits E, Giannini LA, Brouwer N, Melhem S, Seilhean D, Le Ber I, Brainbank Neuro-CEB Neuropathology Network, Kamermans A, Kooij G, de Vries HE, Boddeke EW. Neurovascular dysfunction in GRN-associated frontotemporal dementia identified by single-nucleus RNA sequencing of human cerebral cortex.

652

653

654

Nature neuroscience. 2022 Aug;25(8):1034-48. [https://doi.org/10.1038/s41593-](https://doi.org/10.1038/s41593-022-01124-3)

655

[022-01124-3](https://doi.org/10.1038/s41593-022-01124-3)

656

6. Malpetti M, Rittman T, Jones PS, Cope TE, Passamonti L, Bevan-Jones WR, Patterson K, Fryer TD, Hong YT, Aigbirhio FI, O'Brien JT. In vivo PET imaging of neuroinflammation in familial frontotemporal dementia. Journal of Neurology,

657

658

659

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

- 660 Neurosurgery & Psychiatry. 2020 Oct 29. [https://doi.org/10.1136/jnnp-2020-](https://doi.org/10.1136/jnnp-2020-323698)
661 [323698](https://doi.org/10.1136/jnnp-2020-323698)
- 662 **7.** Du AT, Jahng GH, Hayasaka S, Kramer JH, Rosen HJ, Gorno-Tempini ML,
663 Rankin KP, Miller BL, Weiner MW, Schuff N. Hypoperfusion in frontotemporal
664 dementia and Alzheimer disease by arterial spin labeling MRI. *Neurology*. 2006
665 Oct 10;67(7):1215-20.
- 666 **8.** Mutsaerts HJ, Mirza SS, Petr J, Thomas DL, Cash DM, Bocchetta M, De Vita E,
667 Metcalf AW, Shirzadi Z, Robertson AD, Tartaglia MC. Cerebral perfusion
668 changes in presymptomatic genetic frontotemporal dementia: a GENFI study.
669 *Brain*. 2019 Apr 1;142(4):1108-20. <https://doi.org/10.1093/brain/awz039>
- 670 **9.** Dopfer EG, Chalos V, Ghariq E, den Heijer T, Hafkemeijer A, Jiskoot LC, de
671 Koning I, Seelaar H, van Minkelen R, van Osch MJ, Rombouts SA. Cerebral
672 blood flow in presymptomatic MAPT and GRN mutation carriers: a longitudinal
673 arterial spin labeling study. *NeuroImage: Clinical*. 2016 Feb 1;12:460-5.
674 <https://doi.org/10.1016/j.nicl.2016.08.001>
- 675 **10.** Thal DR, von Arnim CA, Griffin WS, Mrak RE, Walker L, Attems J, Arzberger
676 T. Frontotemporal lobar degeneration FTLT-tau: preclinical lesions, vascular, and
677 Alzheimer-related co-pathologies. *Journal of neural transmission*. 2015
678 Jul;122:1007-18. <https://doi.org/10.1007/s00702-014-1360-6>
- 679 **11.** Willie CK, Tzeng YC, Fisher JA, Ainslie PN. Integrative regulation of human
680 brain blood flow. *The Journal of physiology*. 2014 Mar 1;592(5):841-59.
681 <https://doi.org/10.1113/jphysiol.2013.268953>
- 682 **12.** Jensen KE, Thomsen C, Henriksen O. In vivo measurement of intracellular pH in
683 human brain during different tensions of carbon dioxide in arterial blood. *A*

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

- 684 31P-NMR study. *Acta physiologica scandinavica*. 1988 Oct;134(2):295-8.
685 <https://doi.org/10.1111/j.1748-1716.1988.tb08492.x>
- 686 **13.** Lassen NA. Brain extracellular pH: the main factor controlling cerebral blood
687 flow. *Scandinavian journal of clinical and laboratory investigation*. 1968 Jan
688 1;22(4):247-51.
- 689 **14.** Reich T, Rusinek H. Cerebral cortical and white matter reactivity to carbon
690 dioxide. *Stroke*. 1989 Apr;20(4):453-7. <https://doi.org/10.1161/01.STR.20.4.453>
- 691 **15.** Tsuda Y, Hartmann A. Changes in hyperfrontality of cerebral blood flow and
692 carbon dioxide reactivity with age. *Stroke*. 1989 Dec;20(12):1667-73.
693 <https://doi.org/10.1161/01.STR.20.12.1667>
- 694 **16.** Brandes RP, Fleming I, Busse R. Endothelial aging. *Cardiovascular research*.
695 2005 May 1;66(2):286-94. <https://doi.org/10.1016/j.cardiores.2004.12.027>
- 696 **17.** Haight TJ, Bryan RN, Erus G, Davatzikos C, Jacobs DR, D'Esposito M, Lewis
697 CE, Launer LJ. Vascular risk factors, cerebrovascular reactivity, and the default-
698 mode brain network. *Neuroimage*. 2015 Jul 15;115:7-16.
699 <https://doi.org/10.1016/j.neuroimage.2015.04.039>
- 700 **18.** Cantin S, Villien M, Moreaud O, Tropres I, Keignart S, Chipon E, Le Bas JF,
701 Warnking J, Krainik A. Impaired cerebral vasoreactivity to CO₂ in Alzheimer's
702 disease using BOLD fMRI. *Neuroimage*. 2011 Sep 15;58(2):579-87.
703 <https://doi.org/10.1016/j.neuroimage.2011.06.070>
- 704 **19.** Richiardi J, Monsch AU, Haas T, Barkhof F, Van de Ville D, Radü EW, Kressig
705 RW, Haller S. Altered cerebrovascular reactivity velocity in mild cognitive
706 impairment and Alzheimer's disease. *Neurobiology of aging*. 2015 Jan
707 1;36(1):33-41. <https://doi.org/10.1016/j.neurobiolaging.2014.07.020>

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

- 708 **20.** Birn RM, Diamond JB, Smith MA, Bandettini PA. Separating respiratory-
709 variation-related fluctuations from neuronal-activity-related fluctuations in fMRI.
710 Neuroimage. 2006 Jul 15;31(4):1536-48.
711 <https://doi.org/10.1016/j.neuroimage.2006.02.048>
- 712 **21.** Shmueli K, van Gelderen P, de Zwart JA, Horovitz SG, Fukunaga M, Jansma JM,
713 Duyn JH. Low-frequency fluctuations in the cardiac rate as a source of variance
714 in the resting-state fMRI BOLD signal. Neuroimage. 2007 Nov 1;38(2):306-20.
715 Shmueli K, van Gelderen P, de Zwart JA, Horovitz SG, Fukunaga M, Jansma JM,
716 Duyn JH. Low-frequency fluctuations in the cardiac rate as a source of variance
717 in the resting-state fMRI BOLD signal. Neuroimage. 2007 Nov 1;38(2):306-20.
718 <https://doi.org/10.1016/j.neuroimage.2007.07.037>
- 719 **22.** Golestani AM, Wei LL, Chen JJ. Quantitative mapping of cerebrovascular
720 reactivity using resting-state BOLD fMRI: validation in healthy adults.
721 Neuroimage. 2016 Sep 1;138:147-63.
722 <https://doi.org/10.1016/j.neuroimage.2016.05.025>
- 723 **23.** Kannurpatti SS, Biswal BB. Detection and scaling of task-induced fMRI-BOLD
724 response using resting state fluctuations. Neuroimage. 2008 May 1;40(4):1567-
725 74. <https://doi.org/10.1016/j.neuroimage.2007.09.040>
- 726 **24.** Liu P, Li Y, Pinho M, Park DC, Welch BG, Lu H. Cerebrovascular reactivity
727 mapping without gas challenges. Neuroimage. 2017 Feb 1;146:320-6.
- 728 **25.** Rostrup E, Larsson HB, Toft PB, Garde K, Thomsen C, Ring P, S ndergaard L,
729 Henriksen O. Functional MRI of CO2 induced increase in cerebral perfusion.
730 NMR in Biomedicine. 1994 Mar;7(1-2):29-34.
731 <https://doi.org/10.1002/nbm.1940070106>

- 732 **26.** Tsvetanov KA, Henson RN, Rowe JB. Separating vascular and neuronal effects
733 of age on fMRI BOLD signals. *Philosophical Transactions of the Royal Society*
734 B. 2021 Jan 4;376(1815):20190631. <https://doi.org/10.1098/rstb.2019.0631>
- 735 **27.** Kannurpatti SS, Motes MA, Biswal BB, Rypma B. Assessment of unconstrained
736 cerebrovascular reactivity marker for large age-range FMRI studies. *PloS one*.
737 2014 Feb 13;9(2):e88751. <https://doi.org/10.1371/journal.pone.0088751>
- 738 **28.** Tsvetanov KA, Henson RN, Tyler LK, Davis SW, Shafto MA, Taylor JR,
739 Williams N, Rowe JB. The effect of ageing on fMRI: Correction for the
740 confounding effects of vascular reactivity evaluated by joint fMRI and MEG in
741 335 adults. *Human brain mapping*. 2015 Jun;36(6):2248-69.
742 <https://doi.org/10.1002/hbm.22768>
- 743 **29.** Tsvetanov KA, Henson RN, Jones PS, Mutsaerts H, Fuhrmann D, Tyler LK,
744 CamCAN, Rowe JB. The effects of age on resting-state BOLD signal
745 variability is explained by cardiovascular and cerebrovascular factors.
746 *Psychophysiology*. 2021 Jul;58(7):e13714. <https://doi.org/10.1111/psyp.13714>
- 747 **30.** Su J, Wang M, Ban S, Wang L, Cheng X, Hua F, Tang Y, Zhou H, Zhai Y, Du X,
748 Liu J. Relationship between changes in resting-state spontaneous brain activity
749 and cognitive impairment in patients with CADASIL. *The Journal of Headache*
750 and Pain. 2019 Dec;20:1-1. <https://doi.org/10.1186/s10194-019-0982-3>
- 751 **31.** Nair VA, Raut RV, Prabhakaran V. Investigating the blood oxygenation level-
752 dependent functional MRI response to a verbal fluency task in early stroke before
753 and after hemodynamic scaling. *Frontiers in Neurology*. 2017 Jun 19;8:283.
754 <https://doi.org/10.3389/fneur.2017.00283>
- 755 **32.** Millar PR, Ances BM, Gordon BA, Benzinger TL, Fagan AM, Morris JC, Balota
756 DA. Evaluating resting-state BOLD variability in relation to biomarkers of

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

- 757 preclinical Alzheimer's disease. *Neurobiology of aging*. 2020 Dec 1;96:233-45.
758 <https://doi.org/10.1016/j.neurobiolaging.2020.08.007>
- 759 **33.** Tsvetanov KA, Spindler LR, Stamatakis EA, Newcombe VF, Lupson VC,
760 Chatfield DA, Manktelow AE, Outtrim JG, Elmer A, Kingston N, Bradley JR.
761 Hospitalisation for COVID-19 predicts long lasting cerebrovascular impairment:
762 A prospective observational cohort study. *NeuroImage: Clinical*. 2022 Jan
763 1;36:103253. <https://doi.org/10.1016/j.nicl.2022.103253>
- 764 **34.** Morris JC, Weintraub S, Chui HC, Cummings J, DeCarli C, Ferris S, Foster NL,
765 Galasko D, Graff-Radford N, Peskind ER, Beekly D. The Uniform Data Set
766 (UDS): clinical and cognitive variables and descriptive data from Alzheimer
767 Disease Centers. *Alzheimer Disease & Associated Disorders*. 2006 Oct
768 1;20(4):210-6. <https://doi.org/10.1097/01.wad.0000213865.09806.92>
- 769 **35.** Rohrer JD, Nicholas JM, Cash DM, Van Swieten J, Dopper E, Jiskoot L, Van
770 Minkelen R, Rombouts SA, Cardoso MJ, Clegg S, Espak M. Presymptomatic
771 cognitive and neuroanatomical changes in genetic frontotemporal dementia in the
772 Genetic Frontotemporal dementia Initiative (GENFI) study: a cross-sectional
773 analysis. *The Lancet Neurology*. 2015 Mar 1;14(3):253-62.
774 [https://doi.org/10.1016/S1474-4422\(14\)70324-2](https://doi.org/10.1016/S1474-4422(14)70324-2)
- 775 **36.** Van Buuren S, Groothuis-Oudshoorn K. mice: Multivariate imputation by
776 chained equations in R. *Journal of statistical software*. 2011 Dec 12;45:1-67.
777 <https://doi.org/10.18637/jss.v045.i03>
- 778 **37.** Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. Fsl.
779 *Neuroimage*. 2012 Aug 15;62(2):782-90.
780 <https://doi.org/10.1016/j.neuroimage.2011.09.015>

- 781 **38.** Smith SM, Jenkinson M, Woolrich MW, Beckmann CF, Behrens TE, Johansen-
782 Berg H, Bannister PR, De Luca M, Drobnjak I, Flitney DE, Niazy RK. Advances
783 in functional and structural MR image analysis and implementation as FSL.
784 Neuroimage. 2004 Jan 1;23:S208-19.
785 <https://doi.org/10.1016/j.neuroimage.2004.07.051>
- 786 **39.** Penny WD, Friston KJ, Ashburner JT, Kiebel SJ, Nichols TE, editors. Statistical
787 parametric mapping: the analysis of functional brain images. Elsevier; 2011 Apr
788 28.
- 789 **40.** Jenkinson M, Bannister P, Brady M, Smith S. Improved optimization for the
790 robust and accurate linear registration and motion correction of brain images.
791 Neuroimage. 2002 Oct 1;17(2):825-41. <https://doi.org/10.1006/nimg.2002.1132>
- 792 **41.** Pruim RH, Mennes M, van Rooij D, Llera A, Buitelaar JK, Beckmann CF. ICA-
793 AROMA: A robust ICA-based strategy for removing motion artifacts from fMRI
794 data. Neuroimage. 2015 May 15;112:267-77.
795 <https://doi.org/10.1016/j.neuroimage.2015.02.064>
- 796 **42.** Geerligs L, Tsvetanov KA, Henson RN. Challenges in measuring individual
797 differences in functional connectivity using fMRI: the case of healthy aging.
798 Human brain mapping. 2017 Aug;38(8):4125-56.
799 <https://doi.org/10.1002/hbm.23653>
- 800 **43.** Satterthwaite TD, Elliott MA, Gerraty RT, Ruparel K, Loughhead J, Calkins ME,
801 Eickhoff SB, Hakonarson H, Gur RC, Gur RE, Wolf DH. An improved
802 framework for confound regression and filtering for control of motion artifact in
803 the preprocessing of resting-state functional connectivity data. Neuroimage. 2013
804 Jan 1;64:240-56. <https://doi.org/10.1016/j.neuroimage.2012.08.052>

- 805 **44.** Xu L, Groth KM, Pearlson G, Schretlen DJ, Calhoun VD. Source-based
806 morphometry: The use of independent component analysis to identify gray matter
807 differences with application to schizophrenia. *Human brain mapping*. 2009
808 Mar;30(3):711-24. <https://doi.org/10.1002/hbm.20540>
- 809 **45.** Hui M, Li J, Wen X, Yao L, Long Z. An empirical comparison of information-
810 theoretic criteria in estimating the number of independent components of fMRI
811 data. *PloS one*. 2011 Dec 27;6(12):e29274.
812 <https://doi.org/10.1371/journal.pone.0029274>
- 813 **46.** Li YO, Adalı T, Calhoun VD. Estimating the number of independent components
814 for functional magnetic resonance imaging data. *Human brain mapping*. 2007
815 Nov;28(11):1251-66. <https://doi.org/10.1002/hbm.20359>
- 816 **47.** Rissanen J. Modeling by shortest data description. *Automatica*. 1978 Sep
817 1;14(5):465-71. [https://doi.org/10.1016/0005-1098\(78\)90005-5](https://doi.org/10.1016/0005-1098(78)90005-5)
- 818 **48.** Himberg J, Hyvärinen A, Esposito F. Validating the independent components of
819 neuroimaging time series via clustering and visualization. *Neuroimage*. 2004 Jul
820 1;22(3):1214-22. <https://doi.org/10.1016/j.neuroimage.2004.03.027>
- 821 **49.** Millar PR, Petersen SE, Ances BM, Gordon BA, Benzinger TL, Morris JC,
822 Balota DA. Evaluating the sensitivity of resting-state BOLD variability to age and
823 cognition after controlling for motion and cardiovascular influences: a network-
824 based approach. *Cerebral Cortex*. 2020 Nov;30(11):5686-701.
825 <https://doi.org/10.1093/cercor/bhaa138>
- 826 **50.** Moore KM, Nicholas J, Grossman M, McMillan CT, Irwin DJ, Massimo L, Van
827 Deerlin VM, Warren JD, Fox NC, Rossor MN, Mead S. Age at symptom onset
828 and death and disease duration in genetic frontotemporal dementia: an

- 829 international retrospective cohort study. *The Lancet Neurology*. 2020 Feb
830 1;19(2):145-56. [https://doi.org/10.1016/S1474-4422\(19\)30394-1](https://doi.org/10.1016/S1474-4422(19)30394-1)
- 831 **51.** Chen J, Liu J, Calhoun VD, Arias-Vasquez A, Zwiers MP, Gupta CN, Franke B,
832 Turner JA. Exploration of scanning effects in multi-site structural MRI studies.
833 *Journal of neuroscience methods*. 2014 Jun 15;230:37-50.
834 <https://doi.org/10.1016/j.jneumeth.2014.04.023>
- 835 **52.** Faria AV, Joel SE, Zhang Y, Oishi K, van Zijl PC, Miller MI, Pekar JJ, Mori S.
836 Atlas-based analysis of resting-state functional connectivity: Evaluation for
837 reproducibility and multi-modal anatomy–function correlation studies.
838 *Neuroimage*. 2012 Jul 2;61(3):613-21.
839 <https://doi.org/10.1016/j.neuroimage.2012.03.078>
- 840 **53.** Flück D, Beaudin AE, Steinback CD, Kumarpillai G, Shobha N, McCreary CR,
841 Peca S, Smith EE, Poulin MJ. Effects of aging on the association between
842 cerebrovascular responses to visual stimulation, hypercapnia and arterial stiffness.
843 *Frontiers in physiology*. 2014 Feb 19;5:49.
844 <https://doi.org/10.3389/fphys.2014.00049>
- 845 **54.** Hosp JA, Dressing A, Blazhenets G, Bormann T, Rau A, Schwabenland M,
846 Thurow J, Wagner D, Waller C, Niesen WD, Frings L. Cognitive impairment and
847 altered cerebral glucose metabolism in the subacute stage of COVID-19. *Brain*.
848 2021 Apr 1;144(4):1263-76.
- 849 **55.** Yezhuvath US, Uh J, Cheng Y, Martin-Cook K, Weiner M, Diaz-Arrastia R, van
850 Osch M, Lu H. Forebrain-dominant deficit in cerebrovascular reactivity in
851 Alzheimer's disease. *Neurobiology of aging*. 2012 Jan 1;33(1):75-82.
852 <https://doi.org/10.1016/j.neurobiolaging.2010.02.005>

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

- 853 **56.** Cash DM, Bocchetta M, Thomas DL, Dick KM, van Swieten JC, Borroni B,
854 Galimberti D, Masellis M, Tartaglia MC, Rowe JB, Graff C. Patterns of gray
855 matter atrophy in genetic frontotemporal dementia: results from the GENFI study.
856 Neurobiology of aging. 2018 Feb 1;62:191-6.
857 <https://doi.org/10.1016/j.neurobiolaging.2017.10.008>
- 858 **57.** Tsvetanov KA, Gazzina S, Jones PS, van Swieten J, Borroni B, Sanchez Valle
859 R, Moreno F, Laforce Jr R, Graff C, Synofzik M, Galimberti D. Brain functional
860 network integrity sustains cognitive function despite atrophy in presymptomatic
861 genetic frontotemporal dementia. Alzheimer's & Dementia. 2021 Mar;17(3):500-
862 14. <https://doi.org/10.1002/alz.12209>
- 863 **58.** Mutsaerts HJ, Petr J, Thomas DL, De Vita E, Cash DM, van Osch MJ, Golay X,
864 Groot PF, Ourselin S, van Swieten J, Laforce Jr R. Comparison of arterial spin
865 labeling registration strategies in the multi-center GENetic frontotemporal
866 dementia initiative (GENFI). Journal of Magnetic Resonance Imaging. 2018
867 Jan;47(1):131-40. <https://doi.org/10.1002/jmri.25751>
- 868 **59.** Menon V, Uddin LQ. Saliency, switching, attention and control: a network model
869 of insula function. Brain structure and function. 2010 Jun;214:655-67.
870 <https://doi.org/10.1007/s00429-010-0262-0>
- 871 **60.** Seeley WW. Anterior insula degeneration in frontotemporal dementia. Brain
872 Structure and Function. 2010 Jun;214:465-75. [https://doi.org/10.1007/s00429-
873 010-0263-z](https://doi.org/10.1007/s00429-010-0263-z)
- 874 **61.** De la Torre JC. Alzheimer disease as a vascular disorder: nosological evidence.
875 Stroke. 2002 Apr 1;33(4):1152-62.
876 <https://doi.org/10.1161/01.STR.0000014421.15948.67>

- 877 **62.** Iadecola C. Neurovascular regulation in the normal brain and in Alzheimer's
878 disease. *Nature Reviews Neuroscience*. 2004 May 1;5(5):347-60.
879 <https://doi.org/10.1038/nrn1387>
- 880 **63.** Chun MY, Jang H, Kim SJ, Park YH, Yun J, Lockhart SN, Weiner M, De Carli
881 C, Moon SH, Choi JY, Nam KR. Emerging role of vascular burden in AT (N)
882 classification in individuals with Alzheimer's and concomitant cerebrovascular
883 burdens. *Journal of Neurology, Neurosurgery & Psychiatry*. 2024 Jan 1;95(1):44-
884 51. <https://doi.org/10.1136/jnnp-2023-331603>
- 885 **64.** Claassen JA, Jansen RW. Cholinergically mediated augmentation of cerebral
886 perfusion in alzheimer's disease and related cognitive disorders: the cholinergic-
887 vascular hypothesis. *The Journals of Gerontology Series A: Biological Sciences*
888 and *Medical Sciences*. 2006 Mar 1;61(3):267-71.
889 <https://doi.org/10.1093/gerona/61.3.267>
- 890 **65.** Lyons D, Roy S, Patel M, Benjamin N, Swift CG. Impaired nitric oxide-mediated
891 vasodilatation and total body nitric oxide production in healthy old age. *Clinical*
892 *Science*. 1997 Dec 1;93(6):519-25. <https://doi.org/10.1042/cs0930519>
- 893 **66.** Makedonov I, Black SE, MacIntosh BJ. BOLD fMRI in the white matter as a
894 marker of aging and small vessel disease. *PloS one*. 2013 Jul 2;8(7):e67652.
895 <https://doi.org/10.1371/journal.pone.0067652>
- 896 **67.** Premi E, Calhoun VD, Diano M, Gazzina S, Cosseddu M, Alberici A, Archetti S,
897 Paternicò D, Gasparotti R, van Swieten J, Galimberti D. The inner fluctuations of
898 the brain in presymptomatic frontotemporal dementia: the chronnectome
899 fingerprint. *Neuroimage*. 2019 Apr 1;189:645-54.
900 <https://doi.org/10.1016/j.neuroimage.2019.01.080>

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

- 901 **68.** Liu X, Tyler LK, CamCAN, Rowe JB, Tsvetanov KA. Multimodal fusion
902 analysis of functional, cerebrovascular, and structural neuroimaging in healthy
903 aging subjects. *Human brain mapping*. 2022 Dec 15;43(18):5490-508.
904 <https://doi.org/10.1002/hbm.26025>
- 905 **69.** Rohrer JD, Ridgway GR, Modat M, Ourselin S, Mead S, Fox NC, Rossor MN,
906 Warren JD. Distinct profiles of brain atrophy in frontotemporal lobar
907 degeneration caused by progranulin and tau mutations. *Neuroimage*. 2010 Nov
908 15;53(3):1070-6. <https://doi.org/10.1016/j.neuroimage.2009.12.088>
- 909 **70.** Sur S, Lin Z, Li Y, Yasar S, Rosenberg P, Moghekar A, Hou X, Kalyani R, Hazel
910 K, Pottanat G, Xu C. Association of cerebrovascular reactivity and Alzheimer
911 pathologic markers with cognitive performance. *Neurology*. 2020 Aug
912 25;95(8):e962-72. <https://doi.org/10.1212/WNL.00000000000010133>
- 913 **71.** Liu X, Tyler LK, Davis SW, Rowe JB, Tsvetanov KA. Cognition's dependence
914 on functional network integrity with age is conditional on structural network
915 integrity. *Neurobiology of Aging*. 2023 Sep 1;129:195-208.
916 <https://doi.org/10.1016/j.neurobiolaging.2023.06.001>
- 917 **72.** Passamonti L, Tsvetanov KA, Jones PS, Bevan-Jones WR, Arnold R, Borchert
918 RJ, Mak E, Su L, O'brien JT, Rowe JB. Neuroinflammation and functional
919 connectivity in Alzheimer's disease: interactive influences on cognitive
920 performance. *Journal of Neuroscience*. 2019 Sep 4;39(36):7218-26.
921 <https://doi.org/10.1523/JNEUROSCI.2574-18.2019>
- 922 **73.** Tsvetanov KA, Henson RN, Tyler LK, Razi A, Geerligs L, Ham TE, Rowe JB.
923 Extrinsic and intrinsic brain network connectivity maintains cognition across the
924 lifespan despite accelerated decay of regional brain activation. *Journal of*

Impaired Cerebrovascular Reactivity in Genetic Frontotemporal Dementia

- 925 Neuroscience. 2016 Mar 16;36(11):3115-26.
- 926 <https://doi.org/10.1523/JNEUROSCI.2733-15.2016>
- 927 **74.** Tsvetanov KA, Ye Z, Hughes L, Samu D, Treder MS, Wolpe N, Tyler LK, Rowe
- 928 JB. Activity and connectivity differences underlying inhibitory control across the
- 929 adult life span. *Journal of Neuroscience*. 2018 Sep 5;38(36):7887-900.
- 930 <https://doi.org/10.1523/JNEUROSCI.2919-17.2018>
- 931 **75.** Wu S, Tyler LK, Henson RN, Rowe JB, Tsvetanov KA. Cerebral blood flow
- 932 predicts multiple demand network activity and fluid intelligence across the adult
- 933 lifespan. *Neurobiology of aging*. 2023 Jan 1;121:1-4.
- 934 <https://doi.org/10.1016/j.neurobiolaging.2022.09.006>
- 935
- 936

Cerebrovascular reactivity impairment in genetic frontotemporal dementia

Table 1. Demographic information of participants included in the analysis, grouped by genetic status as non-carriers, pre-symptomatic carriers, and symptomatic carriers

Demographics	Sample	NC	PSC	SC	Group comparison, P value*			
					Sample	NC vs SC	PSC vs SC	NC vs PSC
Total N	673	265 (39.38)	284 (42.2)	124 (18.42)				
Family mutation								.126
<i>C9orf72</i>	264 (39.23)		107	61				
<i>GRN</i>	276 (41.01)		123	40				
<i>MAPT</i>	133 (19.76)		54	23				
Age (years)	48.17±13.43	45.95±13.09	43.93±11.4	62.64±7.43	<.001	<.001	<.001	.132
Sex ratio f:m	371:302	153:112	165:119	53:71	.009	.006	.004	.931
Estimated years from onset	-10.62±13.40	-13.21±13.47	-14.30±11.63	3.32±6.24	<.001	<.001	<.001	.569
Education (years)	14.18±3.45	14.51±3.35	14.50±3.36	12.72±3.53	<.001	<.001	<.001	.998

Values indicate count (percentage) or mean ± standard deviation.

*P values are the result of F test or χ^2 test as appropriate. Bold numbers denote statistical significance at $p < 0.05$ level.

Abbreviations: *C9orf72*, chromosome 9 open reading frame 72; *GRN*, progranulin; *MAPT*, microtubule-associated protein tau. NC, non-carrier; PSC, pre-symptomatic mutation carrier; SC, symptomatic mutation carrier. f, female; m, male.

Cerebrovascular reactivity impairment in genetic frontotemporal dementia

Table 2. Multiple regression analysis results of independent component (IC) subject loadings from independent component analysis (model ' $RSFA_{IC} \sim I + Genetic\ status * Age + Sex + Handedness + Scanning\ Site$ ')

Predictor of interest	Model Adjusted R ²	β	T	Uncorrected P	FDR- corrected P*
IC 4 – Posterior cingulate cortex/precuneus					
	0.62				
Age		-0.09	-3.59	<.001	.001
Genetic status		-0.05	-1.77	.078	.124
Genetic status*Age		-0.05	-2.00	.046	.085
IC 17 – Posterior parietal association areas					
	0.54				
Age		-0.13	-4.27	<.001	<.001
Genetic status		-0.06	-1.80	.072	.098
Genetic status*Age		-0.06	-2.17	.030	.048
IC 21 – Right lateral prefrontal cortex					
	0.44				
Age		-0.11	-3.33	<.001	.004
Genetic status		-0.10	-2.68	.008	.021
Genetic status*Age		-0.07	-2.31	.021	.046
IC 23 – Left lateral prefrontal cortex					
	0.49				
Age		-0.22	-7.22	<.001	<.001

Genetic status	-0.06	-1.87	.062	.168
Genetic status*Age	-0.08	-2.52	.012	.044

RSFA differences across groups of interest following robust multiple linear regression analysis on component-based RSFA maps. Estimated regression parameters, t values, and p values are shown for main effects across the entire sample. Outcomes of interest are the RSFA-IC loadings associated with ICA components within GM regions where case-control differences are found. Models are adjusted for sex, handedness, and scanning site.

* P values are FDR-corrected at the 0.05 level in comparisons across the whole sample (all genetic status groups combined). Bold numbers indicate that p values are statistically significant.

Cerebrovascular reactivity impairment in genetic frontotemporal dementia

Table 3. Multiple regression analysis results following voxel-based region of interest analysis (model ' $RSFA_{Voxel} \sim I + Genetic\ Status * Age + Sex + Handedness + Scanning\ Site$ ')

Predictor of interest	Model Adjusted R ²	β	T	Uncorrected P	FDR- corrected P*
Left middle frontal gyrus	0.23				
Age		-0.09	-2.51	.012	.034
Genetic status		-0.14	-3.25	.001	.005
Genetic status*Age		-0.16	-4.28	<.001	<.001
Right middle frontal gyrus	0.25				
Age		-0.13	-3.72	<.001	.002
Genetic status		-0.15	-3.72	<.001	.002
Genetic status*Age		-0.08	-2.25	.025	.041
Left superior frontal gyrus	0.17				
Age		-0.05	-1.37	.170	.320
Genetic status		-0.19	-4.45	<.001	<.001
Genetic status*Age		-0.08	-2.16	.031	.093
Right superior frontal gyrus	0.26				
Age		-0.10	-2.79	.005	.013
Genetic status		-0.17	-4.09	<.001	<.001
Genetic status*Age		0.06	-1.54	.123	.148

RSFA differences across groups of interest following robust multiple linear regression analysis in several representative ROIs based on voxel-wise univariate analysis on RSFA maps. Estimated regression parameters, t values, and p values are shown for main effects across the entire sample. Outcomes of interest are the RSFA-ROI values associated with each ROI where case-control

differences are found. Models are adjusted for sex, handedness, and scanning site.

**P* values are FDR-corrected at the 0.05 level across the whole sample (all genetic status groups combined). Bold numbers indicate that *p* values are statistically significant.

Genetic	0.09	3.40	.008	0.05	1.91	.057	0.02	0.64	.523	0.05	1.26	.207
status*RSFA												

IC 23 – Left lateral prefrontal cortex

	0.52											
Age	-0.40	-12.85	<.001	0.22	-6.05	<.001	-0.29	-7.24	<.001	-0.36	-8.92	<.001
Genetic status	-0.38	-12.33	<.001	0.67	-17.51	<.001	-0.59	-14.28	<.001	-0.01	-0.19	.846
RSFA	0.11	2.88	.029	0.07	1.69	.091	0.07	1.76	.079	0.07	1.38	.169
Genetic	0.08	2.83	.030	0.01	0.21	.831	0.03	1.06	.289	-0.04	-0.90	.367
status*RSFA												

ROIs based on Voxel-wise Analysis

Left middle frontal gyrus

	0.57											
Age	-0.38	-12.92	<.001	-0.20	-6.01	<.001	-0.28	-7.58	<.001	-0.36	-9.17	<.001
Genetic status	-0.35	-11.51	<.001	-0.60	-15.18	<.001	0.53	-12.82	<.001	-0.003	-0.07	.944
RSFA	0.13	4.42	<.001	0.10	2.95	.003	0.14	4.35	<.001	-0.03	-0.82	.412
Genetic	0.23	8.02	<.001	0.22	6.60	<.001	0.16	4.84	<.001	0.07	1.73	.085
status*RSFA												

Right middle frontal gyrus

	0.54											
Age	-0.41	-13.76	<.001	-0.24	-6.61	<.001	-0.30	-7.63	<.001	-0.37	-9.26	<.001
Genetic status	-0.37	-11.84	<.001	-0.64	-15.63	<.001	-0.58	-14.04	<.001	-0.003	-0.07	.943
RSFA	0.11	3.59	.003	0.07	2.11	.036	0.07	2.15	.032	0.05	1.12	.261
Genetic	0.15	5.25	<.001	0.07	2.06	.040	0.04	1.30	.195	0.05	1.23	.220
status*RSFA												

Left superior frontal gyrus

	0.54											
Age	-0.42	-13.88	<.001	-0.23	-6.47	<.001	-0.30	-7.98	<.001	-0.37	-9.36	<.001

Genetic status	-0.38	-12.10	<.001	-0.64	-16.37	<.001	-0.58	-13.94	<.001	-0.01	-0.17	.861
RSFA	0.08	2.49	.054	0.06	1.85	.065	0.05	1.67	.096	-0.04	-0.85	.398
Genetic	0.14	4.83	<.001	0.12	3.57	<.001	0.09	2.99	.003	0.002	0.06	.951
status*RSFA												

Right superior frontal gyrus

0.54

Age	-0.42	-14.05	<.001	-0.23	-6.59	<.001	-0.30	-7.72	<.001	-0.37	-9.43	<.001
Genetic status	-0.39	-12.64	<.001	-0.67	-17.30	<.001	-0.60	-14.64	<.001	-0.01	-0.29	.769
RSFA	0.03	0.82	.610									
Genetic	0.15	5.29	<.001	0.09	2.91	.004	0.04	1.28	.201	0.07	1.90	.058
status*RSFA												

Cognitive function differences as a function of RSFA and genetic status following robust multiple linear regression analysis in ICA-based components (top panel) and several representative ROIs based on voxel-wise univariate analysis on RSFA maps (bottom panel). Cognitive function is represented by subjects' loading values for PC 1 following PCA on nine cognitive measures. Estimated regression parameters, t values, and *p* values are shown for main effects across the entire sample and sub-groups of interest where relevant. Models are adjusted for age, sex, handedness, and scanning site.

**P*-values are FDR-corrected at the 0.05 level across the whole sample (all genetic status groups combined). Bold numbers indicate that *p* values are statistically significant.

Abbreviations: NC, non-carrier; PSC, pre-symptomatic mutation carrier; SC, symptomatic mutation carrier.

Cerebrovascular reactivity impairment in genetic frontotemporal dementia




Figure 1. Schematic representation of the pre-processing pipeline and analytic approach used in the study.

Cerebrovascular reactivity impairment in genetic frontotemporal dementia




Figure 2. Spatial distribution of 4 independent components (ICs) within neurocognitively meaningful areas (i.e., GM regions) based on ICA on RSFA maps across subjects where differences in IC loading values are found in association with genetic status, age, and genetic status x age interaction. Robust general linear model regression lines for each IC are presented in scatter plots with respective r values on the right side of each IC map. P values are FDR-corrected at the 0.05 level across the whole sample. Group-level spatial maps are overlaid onto the Colin-27 (ch2.nii) structural template of the MNI brain, where intensity values correspond to z-values.

Cerebrovascular reactivity impairment in genetic frontotemporal dementia




Figure 3. Panel A. Regional distribution of RSFA effects based on voxel-wise univariate analysis. Cold colours denote RSFA decreases as a function of genetic status and their interaction with age. Statistical parametric maps are displayed at an uncorrected level of $p < 0.01$ to better visualise regional CVR patterns. Images are overlaid onto the Colin-27 (ch2.nii) structural template of the MNI brain. Panel B. Differences in RSFA in association with genetic status, age, and genetic status x age interaction across groups of interest in several representative ROIs based on voxel-wise univariate analysis. Robust general linear model regression lines for each ROI are presented in scatter plots with respective r values on the right side of each ROI map. P values are FDR-corrected at the 0.05 level across the whole sample. NC, non-carrier; PSC, pre-symptomatic mutation carrier; SC, symptomatic mutation carrier. MFG, middle frontal gyrus; SFG, superior frontal gyrus. ROI, region of interest; VOI, volume of interest.

Cerebrovascular reactivity impairment in genetic frontotemporal dementia




Figure 4. Differences in cognitive function in association with genetic status, RSFA, and genetic status x RSFA interaction across groups of interest. Cognitive function is denoted by subjects' loading values for PC 1 following PCA on nine cognitive measures. Effects are illustrated for ICA-based components within GM areas (top panel) and several representative ROIs based on voxel-wise analysis (bottom panel). Robust general linear model regression lines for each respective IC and ROI are presented in scatter plots with corresponding r values on the right side of a representative slice depicting each IC/ROI map. P values are

FDR-corrected at the 0.05 level across the whole sample. MFG, middle frontal gyrus; SFG, superior frontal gyrus. ROI, region of interest; VOI, volume of interest.